Jentadueto XR

Primary Use

Jentadueto XR is indicated for the management of type 2 diabetes mellitus in adults. It is used as an adjunct to diet and exercise to help lower blood glucose levels. Proper blood sugar management is essential for reducing the risk of long-term complications associated with diabetes.

When It Is Prescribed

This medication is often prescribed for patients who need more than one drug to manage their blood sugar. It may be used in patients who are not achieving their blood sugar goals with metformin or linagliptin alone, or for those who are already taking both medications separately and prefer a single-pill option.

Limitations of Use

Jentadueto XR is not intended for all types of diabetes or related conditions. Its use is limited in the following ways:

• It is not for the treatment of type 1 diabetes.
• It should not be used to treat diabetic ketoacidosis.
• It has not been specifically studied in individuals with a history of pancreatitis.

How Linagliptin Works

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by increasing the levels of natural substances called incretin hormones in the body. These hormones help control blood sugar by:

• Triggering the pancreas to release more insulin when blood sugar levels are high, especially after a meal.
• Signaling the liver to produce less glucose (sugar).

How Metformin Works

Metformin belongs to a class of medicines called biguanides. It helps lower blood sugar through three primary mechanisms:

• It reduces the amount of sugar the liver produces and releases into the bloodstream.
• It decreases the amount of sugar the intestines absorb from the diet.
• It improves insulin sensitivity, which helps the body's cells use its own natural insulin more effectively to remove sugar from the blood.

Extended-Release Technology

The "XR" in Jentadueto XR stands for extended-release. This means the medication is formulated to release the active ingredients slowly into the body over a longer period. This delivery method typically allows for once-daily dosing while maintaining steady levels of the medication in the system.

Common Side Effects

• Diarrhea
• Nausea or vomiting
• Gas or stomach upset
• Headache
• Cold-like symptoms, such as a stuffy or runny nose and sore throat

Serious Side Effects

Seek medical help immediately if you experience any of the following serious symptoms:

• Pancreatitis: Severe pain in the upper stomach that may spread to the back, with or without vomiting.
• Heart Failure: Shortness of breath (even when lying down), swelling in the feet or legs, or sudden weight gain.
• Lactic Acidosis: Unusual muscle pain, feeling cold, dizziness, extreme tiredness, or difficulty breathing.
• Severe Joint Pain: Intense or persistent pain in the joints.
• Skin Reactions: Development of blisters or the breakdown of the outer layer of skin.
• Low Blood Sugar (Hypoglycemia): Symptoms such as shakiness, sweating, fast heartbeat, blurred vision, or confusion, particularly if used with other diabetes medications.
• Vitamin B12 Deficiency: Long-term use may lower vitamin B12 levels in the blood.

Lactic Acidosis

Jentadueto XR has a boxed warning regarding lactic acidosis. This is a rare but life-threatening emergency caused by the buildup of metformin in the blood. The risk is higher in people with kidney impairment, the elderly, those undergoing surgery or radiologic studies using contrast dye, and those who consume excessive alcohol. Symptoms may include unusual tiredness, muscle pain, respiratory distress, or feeling cold in the hands and feet.

Pancreatitis

Inflammation of the pancreas (pancreatitis) has been reported in patients taking linagliptin. Healthcare providers typically monitor for signs such as severe stomach pain that may spread to the back and may be accompanied by vomiting. If pancreatitis is suspected, the medication must be discontinued immediately.

Heart Failure

Studies of medications in the same class as linagliptin have shown an increased risk of heart failure. Patients should be observed for symptoms such as shortness of breath, swelling in the ankles or feet, or sudden weight gain. Those with a history of heart or kidney disease may be at higher risk.

Kidney Function

Metformin is primarily cleared by the kidneys. Jentadueto XR is contraindicated in patients with severe kidney disease (an eGFR below 30 mL/min/1.73 m2). Kidney function is usually assessed before starting the medication and at least annually during treatment.

Hypoglycemia

While Jentadueto XR is unlikely to cause low blood sugar (hypoglycemia) when used alone, the risk increases significantly when it is combined with insulin or insulin secretagogues, such as sulfonylureas. A lower dose of these other medications may be necessary to prevent hypoglycemia.

Additional Precautions

• Vitamin B12 Levels: Long-term use of metformin may lead to a decrease in vitamin B12 levels. Periodic blood tests may be used to monitor for deficiency.
• Severe Joint Pain: Some patients taking DPP-4 inhibitors like linagliptin have reported severe and disabling joint pain. This pain may resolve after stopping the medication.
• Bullous Pemphigoid: This is a serious skin condition involving large, fluid-filled blisters. If blisters or erosions develop, the medication should be stopped.
• Hypersensitivity: Serious allergic reactions, including angioedema (swelling of the face, lips, or throat) and anaphylaxis, have occurred.

Pregnancy

Data on the use of Jentadueto XR, which contains linagliptin and metformin, in pregnant women are limited. While animal studies for linagliptin did not show significant developmental risks at high doses, clinical studies on metformin have not established a clear link between the drug and major birth defects or miscarriage. However, poorly controlled diabetes during pregnancy can increase the risk of complications for both the mother and the developing fetus, including birth defects, stillbirth, and pregnancy-related high blood pressure.

In some premenopausal women who do not ovulate regularly, such as those with polycystic ovary syndrome (PCOS), metformin may cause ovulation to resume. This could increase the risk of an unintended pregnancy. Discussing contraception and pregnancy planning with a healthcare provider is recommended for those in this group.

Breastfeeding

Metformin is known to pass into human breast milk in small amounts. It is currently unknown if linagliptin passes into human breast milk, although it has been found in the milk of laboratory animals. Because the effects on a nursing infant are not fully understood, healthcare providers typically weigh the benefits of breastfeeding against the mother's clinical need for the medication and any potential adverse effects on the child from the drug or the underlying maternal condition.

Dosage Form

Jentadueto XR is supplied as a film-coated, extended-release tablet. This medication is taken by mouth and is formulated to release the active ingredients over an extended period.

Composition

The tablets contain a combination of the following active ingredients:

• Linagliptin
• Metformin hydrochloride

The tablets are produced in different colors and shapes to distinguish between the available versions of the medication.

FDA Approval and Indications

Jentadueto XR is approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It combines two medications: linagliptin and metformin hydrochloride extended-release. This medication is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.

Boxed Warning

The FDA requires a boxed warning for Jentadueto XR due to the risk of lactic acidosis associated with metformin. Lactic acidosis is a rare but serious metabolic complication that can occur if metformin builds up in the blood. If not treated, it can be fatal. Risk factors for developing this condition include:

• Kidney impairment
• Use of certain other medications
• Being 65 years of age or older
• Undergoing radiological studies with contrast dye
• Surgery or other procedures
• Conditions that cause low oxygen (such as heart failure)
• Excessive alcohol intake
• Liver impairment

Regulatory Updates and Safety Communications

Kidney Function Monitoring

The FDA updated the labeling for metformin-containing products to change how kidney function is assessed. Healthcare providers now use the estimated glomerular filtration rate (eGFR) rather than blood creatinine levels to determine if a patient can safely use the medication. Jentadueto XR is contraindicated in patients with severe kidney disease (an eGFR below 30 mL/min/1.73 m2).

Bullous Pemphigoid

The FDA has monitored reports of bullous pemphigoid, a serious skin condition involving blistering, associated with the class of drugs known as DPP-4 inhibitors, which includes linagliptin. Patients are advised to contact a healthcare provider immediately if they develop blisters or skin erosions.

Heart Failure Risk

The FDA has reviewed the risk of heart failure with certain DPP-4 inhibitors. While this risk is primarily associated with other drugs in the class, the FDA requires that healthcare providers consider the risks and benefits of these medications in patients at high risk for heart failure.

Factors Influencing Cost

The price you pay for Jentadueto XR can vary significantly. Common factors that influence the final cost include:

• Insurance Coverage: Most commercial insurance plans and Medicare Part D provide coverage for this medication, but your specific copay or coinsurance will depend on your plan's formulary.
• Pharmacy Choice: Prices can differ between retail pharmacies, mail-order services, and specialty pharmacies.
• Dosage and Quantity: The strength of the tablets and the number of days' supply (such as a 30-day versus a 90-day supply) will affect the total price.

Financial Assistance and Savings

Patients who are uninsured or underinsured may find the cost of Jentadueto XR to be high. There are several options that might help reduce out-of-pocket expenses:

• Manufacturer Savings Cards: The drug manufacturer may offer copay cards for patients with commercial insurance to lower their monthly costs.
• Patient Assistance Programs: Some programs provide the medication at a reduced cost or for free to individuals who meet specific income and eligibility requirements.
• Generic Alternatives: While Jentadueto XR is a brand-name medication, you should consult your healthcare provider or pharmacist to see if lower-cost generic versions of the individual components (linagliptin and metformin) are a suitable alternative for your treatment plan.

Note: Always check with your insurance provider and local pharmacies to get the most accurate and up-to-date pricing information for your specific situation.